HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)

Yale University

Status: Completed

Conditions: Drug Dependence; Human Immunodeficiency Virus; Opiate Addiction; Acquired Immunodeficiency Syndrome

Treatments: Drug: buprenorphine

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT03583138

1011007631b

R01DA030768 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman & Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.

Full description

STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to examine if there are differences in HIV, drug use, and other outcomes between individuals receiving treatment versus individuals actively using, not actively using and not in treatment, and individuals on Methadone, Suboxone, or in some other treatment.

Enrollment: 159 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. HIV+, confirmed by rapid HIV test
2. Meet DSM-IV criteria for opioid dependence
3. 18 years or older
4. Have health insurance that is accepted at Lab Corp.

Exclusion criteria

1. Are <18 years old;
2. Are HIV negative;
3. Are Unable to communicate in English;
4. Are not able to provide informed consent;
5. Do not meet DSM-IV criteria for opioid dependence;
6. Plan to leave the DC area

Trial design

159 participants in 2 patient groups

Buprenorphine

Description:

Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.

Treatment:

Drug: buprenorphine

No buprenorphine

Description:

No buprenorphine